359 related articles for article (PubMed ID: 36032149)
1. A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022.
Zhang J; Chen P; Miao L
Front Immunol; 2022; 13():969196. PubMed ID: 36032149
[TBL] [Abstract][Full Text] [Related]
2. A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.
Miao L; Zhang J; Zhang Z; Wang S; Tang F; Teng M; Li Y
Front Immunol; 2022; 13():840956. PubMed ID: 35371087
[TBL] [Abstract][Full Text] [Related]
3. Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021.
Ou Z; Qiu L; Rong H; Li B; Ren S; Kuang S; Lan T; Lin H; Li Q; Wu F; Cai T; Yan L; Ye Y; Fan S; Li J
Front Immunol; 2022; 13():822004. PubMed ID: 35432345
[TBL] [Abstract][Full Text] [Related]
4. Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis.
Ou L; Su C; Liang L; Duan Q; Li Y; Zang H; He Y; Zeng R; Li Y; Zhou H; Xiao L
Hum Vaccin Immunother; 2023 Dec; 19(3):2267865. PubMed ID: 37846106
[TBL] [Abstract][Full Text] [Related]
5. Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012-2023).
Miao L; Zhang J; Xu W; Qian Q; Zhang G; Yuan Q; Lv Y; Zhang H; Shen C; Wang W
Hum Vaccin Immunother; 2024 Dec; 20(1):2338984. PubMed ID: 38698555
[TBL] [Abstract][Full Text] [Related]
6. Global hotspots and future prospects of chimeric antigen receptor T-cell therapy in cancer research: a bibliometric analysis.
Liu M; Gao Y; Yuan Y; Shi S; Yang K; Wu J; Zhang J; Tian J
Future Oncol; 2020 Apr; 16(10):597-612. PubMed ID: 32207326
[No Abstract] [Full Text] [Related]
7. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.
Zhang G; Deng L; Lu H; Zhang W
Int J Clin Pharm; 2024 Feb; 46(1):186-194. PubMed ID: 38087131
[TBL] [Abstract][Full Text] [Related]
8. A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023.
Li H; Huang Q; Zhang Y
Hum Vaccin Immunother; 2023 Dec; 19(3):2291900. PubMed ID: 38112002
[TBL] [Abstract][Full Text] [Related]
9. Bibliometric study of immunotherapy for hepatocellular carcinoma.
Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
Yilmaz A; Cui H; Caligiuri MA; Yu J
J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
[TBL] [Abstract][Full Text] [Related]
11. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
[TBL] [Abstract][Full Text] [Related]
12. [Research Progress of Chimeric Antigen Receptor Modified NK Cells in the Treatment of Acute Myeloid Leukemia --Review].
Peng XR; Cheng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1905-1909. PubMed ID: 38071081
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study.
Wu X; Deng Z; Zhao Q
Front Immunol; 2022; 13():967076. PubMed ID: 36275770
[TBL] [Abstract][Full Text] [Related]
14. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
15. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
16. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
Zhao Y; Zhou X
Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
[TBL] [Abstract][Full Text] [Related]
17. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
18. Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.
Cheng K; Zhang H; Guo Q; Zhai P; Zhou Y; Yang W; Wang Y; Lu Y; Shen Z; Wu H
Front Immunol; 2022; 13():975695. PubMed ID: 36148235
[TBL] [Abstract][Full Text] [Related]
19. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
